SOBI Stock Overview
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr277.00 |
| 52 Week High | kr302.00 |
| 52 Week Low | kr197.90 |
| Beta | 0.25 |
| 1 Month Change | 6.13% |
| 3 Month Change | 6.54% |
| 1 Year Change | 16.09% |
| 3 Year Change | 87.29% |
| 5 Year Change | 61.05% |
| Change since IPO | 148.43% |
Recent News & Updates
Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More
May 08
Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 27Recent updates
Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More
May 08Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 27Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Apr 24Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 06Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Mar 05Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 15Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors
Jan 17Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Nov 24Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jul 07Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Apr 02Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?
Jan 11These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well
Dec 27Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Sep 28Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jun 26Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet
Mar 28Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?
Nov 17Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Sep 19An Intrinsic Calculation For Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Suggests It's 50% Undervalued
Aug 12Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has A Meaningful Debt Burden
Jun 04Shareholder Returns
| SOBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.8% | 1.5% | 0.4% |
| 1Y | 16.1% | 2.4% | 14.0% |
Return vs Industry: SOBI exceeded the Swedish Biotechs industry which returned 2.4% over the past year.
Return vs Market: SOBI exceeded the Swedish Market which returned 14% over the past year.
Price Volatility
| SOBI volatility | |
|---|---|
| SOBI Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: SOBI has not had significant price volatility in the past 3 months.
Volatility Over Time: SOBI's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,752 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBI fundamental statistics | |
|---|---|
| Market cap | kr94.14b |
| Earnings (TTM) | kr2.14b |
| Revenue (TTM) | kr23.14b |
44.0x
P/E Ratio4.1x
P/S RatioIs SOBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBI income statement (TTM) | |
|---|---|
| Revenue | kr23.14b |
| Cost of Revenue | kr5.41b |
| Gross Profit | kr17.73b |
| Other Expenses | kr15.59b |
| Earnings | kr2.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 16, 2024
| Earnings per share (EPS) | 6.30 |
| Gross Margin | 76.64% |
| Net Profit Margin | 9.26% |
| Debt/Equity Ratio | 52.6% |
How did SOBI perform over the long term?
See historical performance and comparison